Analysts expect Vaxart, Inc. (NASDAQ:VXRT – Get Rating) to post earnings of ($0.17) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.16) and the lowest estimate coming in at ($0.18). Vaxart posted earnings of ($0.14) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 21.4%. The business is expected to report its next quarterly earnings report on Monday, January 1st.
According to Zacks, analysts expect that Vaxart will report full year earnings of ($0.69) per share for the current fiscal year, with EPS estimates ranging from ($0.85) to ($0.53). For the next financial year, analysts forecast that the company will report earnings of ($0.18) per share, with EPS estimates ranging from ($0.85) to $0.52. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Vaxart.
Vaxart (NASDAQ:VXRT – Get Rating) last posted its quarterly earnings data on Thursday, February 24th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.17). Vaxart had a negative return on equity of 36.68% and a negative net margin of 7,900.22%. The company had revenue of $0.07 million during the quarter, compared to analysts’ expectations of $0.18 million. The company’s revenue was down 75.3% on a year-over-year basis.
VXRT opened at $3.86 on Friday. The business has a fifty day moving average of $4.80 and a 200 day moving average of $5.79. Vaxart has a 52-week low of $3.83 and a 52-week high of $11.11. The stock has a market cap of $487.93 million, a P/E ratio of -6.66 and a beta of 0.41.
Several hedge funds have recently modified their holdings of VXRT. Morgan Stanley lifted its holdings in shares of Vaxart by 203.5% in the 2nd quarter. Morgan Stanley now owns 265,935 shares of the biotechnology company’s stock worth $1,992,000 after buying an additional 178,320 shares during the period. Royal Bank of Canada lifted its holdings in shares of Vaxart by 58.0% in the 2nd quarter. Royal Bank of Canada now owns 23,380 shares of the biotechnology company’s stock worth $175,000 after buying an additional 8,578 shares during the period. Invesco Ltd. lifted its holdings in shares of Vaxart by 154.9% in the 2nd quarter. Invesco Ltd. now owns 54,892 shares of the biotechnology company’s stock worth $411,000 after buying an additional 33,360 shares during the period. Strs Ohio lifted its stake in shares of Vaxart by 1,171.4% during the 3rd quarter. Strs Ohio now owns 8,900 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 8,200 shares during the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Vaxart during the 3rd quarter worth $382,000. Institutional investors and hedge funds own 30.51% of the company’s stock.
About Vaxart (Get Rating)
Vaxart, Inc, a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.
- Get a free copy of the StockNews.com research report on Vaxart (VXRT)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- MarketBeat Podcast: 3 Stocks Flashing Buy Signals
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.